April 24, 2008
Chinese officials are touring a New Jersey plant as part of an investigation into possible heparin drug injuries, including death and adverse reactions, suffered by users of heparin, according to CourierPostOnline.com.
The New Jersey facility produces at least 35 million sodium injection vials of heparin per year. The FDA believes that the tainted heparin doses originated from a company in China.
Chinese officials are touring the facility in order to disprove the FDA’s allegations.
Heparin is usually used by people before they undergo certain types of surgery and by kidney patients who use the drug before undergoing dialysis.